Primary Myelosclerosis

hope4cure 249 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Myelofibrosis written for patients
This page has been archived. It has not been updated since 22/03/2010. External links and references may no longer work.

Synonyms: myelofibrosis, agnogenic/idiopathic myeloid metaplasia with myelofibrosis.

This is one of the chronic myeloproliferative disorders. It is an acquired, malignant clonal disorder, characterised by expansion of pluripotent stem cells. They show deranged production of one or more myeloid lines and have a variable tendency to transform to leukaemia.

Incidence

Although this condition is seen at any age, it is most often seen over the age of 50 years. Peak incidence is at 60-70 years.

Prevalence

It is very rare. Approximately 1 case per 300,000 per year. Males and females are equally affected.

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »
  • Marrow fibrosis with either greater or decreased cellularity is a constant feature. The fibrosis is thought to be due to platelet-derived growth factor produced by malignant megakaryocytes. This is a known mitogenic agent for fibroblasts.
  • Primary myelosclerotic marrow is hypocellular due to extensive fibrosis replacing the myeloid and erythrocytic element.
  • Megakaryocytes, which are not always increased in number, are morphologically abnormal.
  • Osteosclerosis is a common finding.
  • As marrow fibrosis progresses the amount of extramedullary myeloid metaplasia increases.
  • The spleen is the primary site of extramedullary metaplasia. The liver, lymph nodes and kidneys can also become involved.

Genomic aberrations are more common than previously thought. Approximately 50% of cases are known to possess an activating JAK2 V617F mutation on chromosome 9.[1][2]

Symptoms

  • Patients may be asymptomatic for some time; 2 years is common. There may be incidental finding with anaemia or splenomegaly.
  • Fatigue and weakness (secondary to anaemia) are common presenting complaints.
  • It may present as unusual bleeding.
  • It may present as early satiety, with accompanying weight loss, and abdominal distension due to splenomegaly. Systemic symptoms are also found: bone pain, night sweats and fever.

Signs

  • FBC reveals moderate-to-severe normochromic, normocytic anaemia.
  • There is anisocytosis with marked poikilocytosis, characterised by teardrop shapes - dacrocytes.
  • Nucleated red blood cells (RBCs) are present.
  • Leukocytosis with immature forms is seen. Leukocyte alkaline phosphatase (LAP) score - a histochemical stain used to identify the neutrophil enzyme in myeloid disease - is normal or unusually high.
  • There are abnormal platelets and sometimes megakaryocyte nuclei are seen.

Not all these features are there in early disease.

End-stage disease can be accompanied by haemorrhagic episodes, infection, heart failure, portal hypertension and acute leukaemic transformation.

General measures

Transfusion of packed RBCs and platelets may be helpful.

Drugs

  • Glucocorticoids help RBC survival time, which is often reduced.
  • Recombinant erythropoetin and hydroxyurea have been used to treat anaemia. Cladribine is particularly useful post-splenectomy with thrombocytopenia and hepatomegaly.[3] Thalidomide was thought to give a good response in 20-60%,[4] but a recent Cochrane review showed that there was no substantial efficacy in anaemic myelosclerotic patients.[5] The placebo group also showed spontaneous periods of remission of anaemia.
  • Testosterone also reduces transfusion requirements, but is poorly tolerated by women.
  • Chemotherapy with hydroxyurea or interferon alfa 2b can reduce splenomegaly. Interferon reduces spleen size in 30-50% of patients with myeloproliferative disease.[6]

Surgical

  • Painful splenomegaly can be treated with radiation or splenectomy.[7] Decision to operate must balance potential palliative gain with postoperative mortality rate of 9%,[3] and morbidity from infection, thrombosis or bleeding of 30%.
  • Allogenic, peripheral bone marrow or stem cell transplant.[8]

Average survival is 5 years, with a range of 1-16 years. The first 2 years are usually asymptomatic. Prognostic factors include:

  • Age
  • Degree of anaemia
  • Degree of leukopenia or leukocytosis
  • Number of circulating blasts
  • Karyotypic abnormalities present and presence of systemic symptoms

If 2 of these are present, median survival is <3 years.[9] If only one factor is present, prognosis is much better - up to 15 years.[10] Patients who present at age <45 years have a survival of <3 years when they present with haemoglobin concentration of 10 g/dL and constitutional symptoms.[10]

Further reading & references

  1. Al-Assar O, Ul-Hassan A, Brown R, et al; Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study. Br J Haematol. 2005 Apr;129(1):66-71.
  2. Reilly JT; Idiopathic myelofibrosis: pathogenesis to treatment. Hematol Oncol. 2006 Jun;24(2):56-63.
  3. Tefferi A, Mesa RA, Nagorney DM, et al; Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000 Apr 1;95(7):2226-33.
  4. Giovanni B, Michelle E, Letizia C, et al; Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma. 2002 Dec;43(12):2301-7.
  5. Abgrall JF, Guibaud I et al. Cochrane Library. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.; August 2006
  6. Gilbert HS; Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer. 1998 Sep 15;83(6):1205-13.
  7. Tefferi A, Huang J, Schwager S, et al; Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007 May 15;109(10):2083-8.
  8. Kroger N, Mesa RA; Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia. 2008 Mar;22(3):474-86. Epub 2008 Jan 10.
  9. Cervantes F, Barosi G, Demory JL, et al; Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998 Aug;102(3):684-90.
  10. Cervantes F, Pereira A, Esteve J, et al; Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997 Jun;97(3):635-40.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Hayley Willacy
Current Version:
Document ID:
2486 (v23)
Last Checked:
22/03/2010
Next Review:
21/03/2015

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for healthcare and news updates.

We would love to hear your feedback!

 
 
Patient Access app - find out more Patient facebook page - Like our page